From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Should you keep on punting growing online sports giant Entain?

By Chris Bailey of Financial Orbit | Thursday 4 March 2021


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


An excitable day today as I had my first Covid-19 vaccine (thanks for all those involved including a stock I have not held for years, AstraZeneca (AZN)) and the further progress at Aviva (AV) was very pleasing. As I noted about the latter here, a couple of weeks ago, its simplification process remains strong. For what it is worth, my own target price has risen up by a few more pence above four quid and there is even a 5% plus dividend yield on offer. The shares are still a strong hold for me. 

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 14:46:41